Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes

Eduardo Garza, Emiliano Fabiani, Nelida Noguera, Paola Panetta, Maria L. Piredda, Loredana Borgia, Luca Maurillo, Gianfranco Catalano, Maria T. Voso, Francesco Lo-Coco

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Somatic mutations of the spliceosome machinery have been recently identified by whole genome analysis in hematologic diseases, such as myelodysplastic syndrome, chronic lymphocytic leukemia, myeloproliferative neoplasms, acute myeloid leukemia, and advanced forms of mastocytosis, and also in nonhematologic conditions. SRSF2 is a member of the serine/arginine-rich family pre-mRNA splicing factors that plays a role in mRNA export from the nucleus and translation. We describe a high-resolution melting (HRM) curve analysis to screen for SRSF2 hotspot mutations in a fast, sensitive, and reliable way. Fifty bone marrow samples from patients with myelodysplastic syndrome were analyzed by the HRM assay and by direct sequencing. HRM screening identified four melting patterns corresponding to a negative (wild-type) group and three different mutated groups. Each mutated group was identified according to the positive control used: P95H, P95L, and P95R, respectively. An HRM mutated pattern was identified in seven patients. Positive and negative results from HRM were compared with direct sequencing results with a sensitivity and specificity of 100% (95% CI, 0.56-1, and 95% CI, 0.89-1, respectively). Analytical sensitivity analysis revealed a detection threshold of up to 1:9 (mutated/wild type) dilution. This rapid screening method may provide useful information for clinical decision making and be helpful to optimize laboratory resources and reduce turnaround time.

Original languageEnglish
Pages (from-to)85-89
Number of pages5
JournalJournal of Molecular Diagnostics
Volume17
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Myelodysplastic Syndromes
Freezing
Mutation
Genes
Spliceosomes
Mastocytosis
Hematologic Diseases
RNA Precursors
B-Cell Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Serine
Arginine
RNA Splicing Factors
Bone Marrow
Genome
Sensitivity and Specificity
Messenger RNA
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Pathology and Forensic Medicine

Cite this

Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes. / Garza, Eduardo; Fabiani, Emiliano; Noguera, Nelida; Panetta, Paola; Piredda, Maria L.; Borgia, Loredana; Maurillo, Luca; Catalano, Gianfranco; Voso, Maria T.; Lo-Coco, Francesco.

In: Journal of Molecular Diagnostics, Vol. 17, No. 1, 01.01.2015, p. 85-89.

Research output: Contribution to journalArticle

Garza, Eduardo ; Fabiani, Emiliano ; Noguera, Nelida ; Panetta, Paola ; Piredda, Maria L. ; Borgia, Loredana ; Maurillo, Luca ; Catalano, Gianfranco ; Voso, Maria T. ; Lo-Coco, Francesco. / Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes. In: Journal of Molecular Diagnostics. 2015 ; Vol. 17, No. 1. pp. 85-89.
@article{9087c3466abe45dd83dea5ecc77c184c,
title = "Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes",
abstract = "Somatic mutations of the spliceosome machinery have been recently identified by whole genome analysis in hematologic diseases, such as myelodysplastic syndrome, chronic lymphocytic leukemia, myeloproliferative neoplasms, acute myeloid leukemia, and advanced forms of mastocytosis, and also in nonhematologic conditions. SRSF2 is a member of the serine/arginine-rich family pre-mRNA splicing factors that plays a role in mRNA export from the nucleus and translation. We describe a high-resolution melting (HRM) curve analysis to screen for SRSF2 hotspot mutations in a fast, sensitive, and reliable way. Fifty bone marrow samples from patients with myelodysplastic syndrome were analyzed by the HRM assay and by direct sequencing. HRM screening identified four melting patterns corresponding to a negative (wild-type) group and three different mutated groups. Each mutated group was identified according to the positive control used: P95H, P95L, and P95R, respectively. An HRM mutated pattern was identified in seven patients. Positive and negative results from HRM were compared with direct sequencing results with a sensitivity and specificity of 100{\%} (95{\%} CI, 0.56-1, and 95{\%} CI, 0.89-1, respectively). Analytical sensitivity analysis revealed a detection threshold of up to 1:9 (mutated/wild type) dilution. This rapid screening method may provide useful information for clinical decision making and be helpful to optimize laboratory resources and reduce turnaround time.",
author = "Eduardo Garza and Emiliano Fabiani and Nelida Noguera and Paola Panetta and Piredda, {Maria L.} and Loredana Borgia and Luca Maurillo and Gianfranco Catalano and Voso, {Maria T.} and Francesco Lo-Coco",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jmoldx.2014.08.002",
language = "English",
volume = "17",
pages = "85--89",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "1",

}

TY - JOUR

T1 - Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes

AU - Garza, Eduardo

AU - Fabiani, Emiliano

AU - Noguera, Nelida

AU - Panetta, Paola

AU - Piredda, Maria L.

AU - Borgia, Loredana

AU - Maurillo, Luca

AU - Catalano, Gianfranco

AU - Voso, Maria T.

AU - Lo-Coco, Francesco

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Somatic mutations of the spliceosome machinery have been recently identified by whole genome analysis in hematologic diseases, such as myelodysplastic syndrome, chronic lymphocytic leukemia, myeloproliferative neoplasms, acute myeloid leukemia, and advanced forms of mastocytosis, and also in nonhematologic conditions. SRSF2 is a member of the serine/arginine-rich family pre-mRNA splicing factors that plays a role in mRNA export from the nucleus and translation. We describe a high-resolution melting (HRM) curve analysis to screen for SRSF2 hotspot mutations in a fast, sensitive, and reliable way. Fifty bone marrow samples from patients with myelodysplastic syndrome were analyzed by the HRM assay and by direct sequencing. HRM screening identified four melting patterns corresponding to a negative (wild-type) group and three different mutated groups. Each mutated group was identified according to the positive control used: P95H, P95L, and P95R, respectively. An HRM mutated pattern was identified in seven patients. Positive and negative results from HRM were compared with direct sequencing results with a sensitivity and specificity of 100% (95% CI, 0.56-1, and 95% CI, 0.89-1, respectively). Analytical sensitivity analysis revealed a detection threshold of up to 1:9 (mutated/wild type) dilution. This rapid screening method may provide useful information for clinical decision making and be helpful to optimize laboratory resources and reduce turnaround time.

AB - Somatic mutations of the spliceosome machinery have been recently identified by whole genome analysis in hematologic diseases, such as myelodysplastic syndrome, chronic lymphocytic leukemia, myeloproliferative neoplasms, acute myeloid leukemia, and advanced forms of mastocytosis, and also in nonhematologic conditions. SRSF2 is a member of the serine/arginine-rich family pre-mRNA splicing factors that plays a role in mRNA export from the nucleus and translation. We describe a high-resolution melting (HRM) curve analysis to screen for SRSF2 hotspot mutations in a fast, sensitive, and reliable way. Fifty bone marrow samples from patients with myelodysplastic syndrome were analyzed by the HRM assay and by direct sequencing. HRM screening identified four melting patterns corresponding to a negative (wild-type) group and three different mutated groups. Each mutated group was identified according to the positive control used: P95H, P95L, and P95R, respectively. An HRM mutated pattern was identified in seven patients. Positive and negative results from HRM were compared with direct sequencing results with a sensitivity and specificity of 100% (95% CI, 0.56-1, and 95% CI, 0.89-1, respectively). Analytical sensitivity analysis revealed a detection threshold of up to 1:9 (mutated/wild type) dilution. This rapid screening method may provide useful information for clinical decision making and be helpful to optimize laboratory resources and reduce turnaround time.

UR - http://www.scopus.com/inward/record.url?scp=84964286165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964286165&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2014.08.002

DO - 10.1016/j.jmoldx.2014.08.002

M3 - Article

VL - 17

SP - 85

EP - 89

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 1

ER -